Pharmacopeia

CWP-0142

Lacosamide

Neurology & Sedation · Level 3

Core pharmacology

Class Group

Antiseizure medication; functionalised amino-acid derivative / sodium-channel modulator.

Main Action

Reduces neuronal hyperexcitability and seizure propagation.

Mechanism of action

Selectively enhances slow inactivation of voltage-gated sodium channels, reducing sustained neuronal firing.

Indications Uses

Focal/partial-onset seizures with or without secondary generalisation; add-on treatment for selected primary generalised tonic-clonic seizures, according to age and formulation indications.

Absorption

Oral bioavailability approximately 100%; peak concentrations about 0.5–4 hours after ingestion; oral solution and tablets are bioequivalent.

Distribution

Volume of distribution approximately 0.6 L/kg; plasma protein binding below 15%.

Metabolism

Partly biotransformed to an O-desmethyl metabolite without known antiepileptic activity; CYP2C19 and other enzymes participate.

Excretion

Predominantly renal excretion of parent drug and metabolites; around 40% of a dose is recovered unchanged in urine. Haemodialysis removes lacosamide.

Half-life

Elimination half-life approximately 13 hours; steady state in around 3 days with twice-daily dosing.

Adverse Effects Toxicity

Dizziness, diplopia, ataxia, nausea; dose-related PR prolongation and possible atrioventricular conduction abnormalities, especially with other conduction-slowing drugs.

Special Points

Check ECG/PR interval in patients with structural heart disease, cardiac conduction abnormalities or concomitant sodium-channel/AV-nodal agents. Renal or hepatic impairment may alter exposure; follow formulation-specific dose guidance.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.